

1.1 **Department of Health**

1.2 **Proposed Permanent Rules Pertaining to Health Risk Limits**

1.3 **4717.7850 USE OF MAXIMUM CONTAMINANT LEVELS.**

1.4 Subpart 1. **Scope.** This part establishes the methods for determining a health risk
1.5 limit based on a maximum contaminant level.

1.6 Subp. 2. **Water level standards.** As authorized by Laws 2007, chapter 147, article
1.7 17, section 2, the maximum contaminant levels for the following chemicals are adopted
1.8 by reference as health risk limits:

1.9 A. Atrazine;

1.10 B. Dichloromethane;

1.11 ~~C. Di(2-ethylhexyl) phthalate;~~

1.12 ~~D. Nitrate (as N);~~

1.13 ~~E. Pentachlorophenol;~~

1.14 ~~F. Simazine;~~

1.15 ~~G. 1,1,2,2-Tetrachloroethylene; and~~

1.16 ~~H. 1,1,2-Trichloroethylene; and~~

1.17 ~~I. 2(2,4,5-Trichlorophenoxy) propionic acid.~~

1.18 **4717.7860 HEALTH RISK LIMITS TABLE.**

1.19 [For text of subps 1 and 2, see M.R.]

1.20 Subp. 2a. Acetaminophen.

1.21 CAS number: 103-90-2

1.22 Year Adopted: 2015

1.23 Volatility: Nonvolatile

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>	
2.1 2.2	<u>HRL (µg/L)</u>	<u>200</u>	<u>200</u>	<u>200 (2)</u>	<u>200 (2)</u>	<u>NA</u>
2.3 2.4	<u>RfD (mg/kg-day)</u>	<u>0.25</u>	<u>0.25</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
2.5	<u>RSC</u>	<u>0.2</u>	<u>0.2</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
2.6 2.7	<u>SF (per mg/kg-day)</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
2.8 2.9	<u>ADAF or AF_{lifetime}</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
2.10 2.11	<u>Intake Rate (L/kg-day)</u>	<u>0.289</u>	<u>0.289</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
2.12 2.13	<u>Endpoints</u>	<u>hepatic (liver) system</u>	<u>hepatic (liver) system</u>	<u>hepatic (liver) system</u>	<u>hepatic (liver) system</u>	<u>=</u>

2.14 [For text of subs 3 to 3d, see M.R.]

2.15 Subp. 3e. Acrylamide.

2.16 CAS number: 79-06-1

2.17 Year Adopted: 2015

2.18 Volatility: Nonvolatile

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>	
2.19 2.20	<u>HRL (µg/L)</u>	<u>ND</u>	<u>7</u>	<u>7 (2)</u>	<u>7 (2)</u>	<u>0.2</u>
2.21 2.22	<u>RfD (mg/kg-day)</u>	<u>=</u>	<u>0.010</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
2.23	<u>RSC</u>	<u>=</u>	<u>0.2</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
2.24 2.25	<u>SF (per mg/kg-day)</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>0.5</u>
2.26 2.27 2.28 2.29 2.30 2.31	<u>ADAF or AF_{lifetime}</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>10 (ADAF_{<2}) 3 (ADAF₂ to <16) 1 (ADAF₁₆₊)</u>

3.1	Intake Rate	=	<u>0.289</u>	<u>(2)</u>	<u>(2)</u>	<u>0.137</u> (<u><2</u>)
3.2	(L/kg-day)					<u>0.047</u> (<u>2 to</u>
3.3						<u><16</u>)
3.4						<u>0.039</u> (<u>16+</u>)
3.5	Endpoints	=	<u>developmental,</u>	<u>developmental,</u>	<u>developmental,</u>	<u>cancer</u>
3.6			<u>male</u>	<u>male</u>	<u>male</u>	
3.7			<u>reproductive</u>	<u>reproductive</u>	<u>reproductive</u>	
3.8			<u>system, nervous</u>	<u>system, nervous</u>	<u>system, nervous</u>	
3.9			<u>system</u>	<u>system</u>	<u>system</u>	

3.10 [For text of subs 4 and 5, see M.R.]

3.11 Subp. 5a. **Bentazon.**

3.12 CAS number: 25057-89-0

3.13 Year Adopted: 2015

3.14 Volatility: Nonvolatile

3.15		<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>
3.16	HRL (µg/L)	<u>400</u>	<u>60</u>	<u>50</u>	<u>30</u>	<u>NA</u>
3.17	RfD	<u>0.22</u>	<u>0.033</u>	<u>0.020</u>	<u>0.0060</u>	=
3.18	(mg/kg-day)					
3.19	RSC	<u>0.5</u>	<u>0.5</u>	<u>0.2</u>	<u>0.2</u>	=
3.20	SF (per	=	=	=	=	=
3.21	mg/kg-day)					
3.22	ADAF or	=	=	=	=	=
3.23	AF_{lifetime}					
3.24	Intake Rate	<u>0.289</u>	<u>0.289</u>	<u>0.077</u>	<u>0.043</u>	=
3.25	(L/kg-day)					
3.26	Endpoints	<u>developmental,</u>	<u>developmental</u>	<u>hematological</u>	<u>thyroid</u>	=
3.27		<u>female</u>		<u>(blood) system</u>		
3.28		<u>reproductive</u>				
3.29		<u>system</u>				

3.30 [For text of subp 6, see M.R.]

3.31 Subp. 6a. [Renumbered subp 6f]

4.1 Subp. 6b. [Renumbered subp 6g]

4.2 Subp. 6c. **Bisphenol A (BPA).**

4.3 CAS number: 80-05-7

4.4 Year Adopted: 2015

4.5 Volatility: Nonvolatile

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>
4.6 <u>HRL (µg/L)</u>	<u>ND</u>	<u>100</u>	<u>20</u>	<u>20 (3)</u>	<u>NA</u>
4.7 <u>RfD</u>	<u>=</u>	<u>0.16</u>	<u>0.0065</u>	<u>(3)</u>	<u>=</u>
4.8 <u>(mg/kg-day)</u>					
4.9 <u>RSC</u>	<u>=</u>	<u>0.2</u>	<u>0.2</u>	<u>(3)</u>	<u>=</u>
4.10 <u>SF (per</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
4.11 <u>mg/kg-day)</u>					
4.12 <u>ADAF or</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
4.13 <u>AF</u>					
4.14 <u>lifetime</u>					
4.15 <u>Intake Rate</u>	<u>=</u>	<u>0.289</u>	<u>0.077</u>	<u>(3)</u>	<u>=</u>
4.16 <u>(L/kg-day)</u>					
4.17 <u>Endpoints</u>	<u>=</u>	<u>developmental,</u>	<u>hepatic (liver)</u>	<u>hepatic (liver)</u>	<u>=</u>
4.18		<u>female</u>	<u>system, renal</u>	<u>system, renal</u>	
4.19		<u>reproductive</u>	<u>(kidney) system</u>	<u>(kidney) system</u>	
4.20		<u>system (E),</u>			
4.21		<u>hepatic (liver)</u>			
4.22		<u>system, male</u>			
4.23		<u>reproductive</u>			
4.24		<u>system (E),</u>			
4.25		<u>renal (kidney)</u>			
4.26		<u>system, thyroid</u>			
4.27		<u>(E)</u>			

4.28 Subp. 6d. **Butyl benzyl phthalate.**

4.29 CAS number: 85-68-7

4.30 Year Adopted: 2015

4.31 Volatility: Low

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>	
5.1						
5.2	<u>HRL (µg/L)</u>	<u>100</u>	<u>100</u>	<u>100 (2)</u>	<u>100 (2)</u>	<u>NA</u>
5.3	<u>RfD</u>	<u>0.15</u>	<u>0.15</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
5.4	<u>(mg/kg-day)</u>					
5.5	<u>RSC</u>	<u>0.2</u>	<u>0.2</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
5.6	<u>SF (per</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
5.7	<u>mg/kg-day)</u>					
5.8	<u>ADAF or</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
5.9	<u>AF</u> _{lifetime}					
5.10	<u>Intake Rate</u>	<u>0.289</u>	<u>0.289</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
5.11	<u>(L/kg-day)</u>					
5.12	<u>Endpoints</u>	<u>developmental</u>	<u>developmental</u>	<u>developmental</u>	<u>developmental</u>	<u>=</u>
5.13		<u>(E)</u>	<u>(E)</u>	<u>(E)</u>	<u>(E)</u>	

5.14 Subp. 6e. Cadmium.5.15 CAS number: 7440-43-95.16 Year Adopted: 20155.17 Volatility: Nonvolatile

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>	
5.18						
5.19	<u>HRL (µg/L)</u>	<u>5</u>	<u>1</u>	<u>1</u>	<u>0.5</u>	<u>NA</u>
5.20	<u>RfD</u>	<u>0.0077</u>	<u>0.0016</u>	<u>0.00044</u>	<u>0.00011</u>	<u>=</u>
5.21	<u>(mg/kg-day)</u>					
5.22	<u>RSC</u>	<u>0.2</u>	<u>0.2</u>	<u>0.2</u>	<u>0.2</u>	<u>=</u>
5.23	<u>SF (per</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
5.24	<u>mg/kg-day)</u>					
5.25	<u>ADAF or</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
5.26	<u>AF</u> _{lifetime}					
5.27	<u>Intake Rate</u>	<u>0.289</u>	<u>0.289</u>	<u>0.077</u>	<u>0.043</u>	<u>=</u>
5.28	<u>(L/kg-day)</u>					
5.29	<u>Endpoints</u>	<u>developmental</u>	<u>developmental,</u>	<u>developmental,</u>	<u>renal (kidney)</u>	<u>=</u>
5.30			<u>nervous system,</u>	<u>skeletal</u>	<u>system, skeletal</u>	
5.31			<u>renal (kidney)</u>			
5.32			<u>system</u>			

6.1 [For text of subps 7 and 8, see M.R.]

6.2 Subp. 8a. [Renumbered subp 8f]

6.3 Subp. 8b. [Renumbered subp 8g]

6.4 Subp. 8c. [Renumbered subp 8h]

6.5 Subp. 8d. [Renumbered subp 8i]

6.6 Subp. 8e. **Dibutyl phthalate.**

6.7 CAS number: 84-74-2

6.8 Year Adopted: 2015

6.9 Volatility: Low

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>
6.10 <u>HRL (µg/L)</u>	<u>20</u>	<u>20</u>	<u>20 (2)</u>	<u>20 (2)</u>	<u>NA</u>
6.11 <u>RfD</u>	<u>0.023</u>	<u>0.023</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
6.12 <u>(mg/kg-day)</u>					
6.13 <u>RSC</u>	<u>0.2</u>	<u>0.2</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
6.14 <u>SF (per</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
6.15 <u>mg/kg-day)</u>					
6.16 <u>ADAF or</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
6.17 <u>AF</u>					
6.18 <u>lifetime</u>					
6.19 <u>Intake Rate</u>	<u>0.289</u>	<u>0.289</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
6.20 <u>(L/kg-day)</u>					
6.21 <u>Endpoints</u>	<u>developmental</u>	<u>developmental</u>	<u>developmental</u>	<u>developmental</u>	<u>=</u>
6.22	<u>(E)</u>	<u>(E)</u>	<u>(E)</u>	<u>(E)</u>	

6.23 [For text of subps 9 to 11, see M.R.]

6.24 Subp. 11a. [Renumbered subp 11d]

6.25 Subp. 11b. [Renumbered subp 11f]

6.26 Subp. 11c. **Di(2-ethylhexyl) phthalate (DEHP).**

7.1 CAS number: 117-81-77.2 Year Adopted: 20157.3 Volatility: Nonvolatile

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>	
7.4 7.5	<u>HRL (µg/L)</u>	<u>20</u>	<u>20</u>	<u>20 (2)</u>	<u>20 (2)</u>	<u>7</u>
7.6 7.7	<u>RfD (mg/kg-day)</u>	<u>0.029</u>	<u>0.029</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
7.8	<u>RSC</u>	<u>0.2</u>	<u>0.2</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
7.9 7.10	<u>SF (per mg/kg-day)</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>0.014</u>
7.11 7.12 7.13 7.14	<u>ADAF or AF_{lifetime}</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>10 (ADAF_{<2})</u> <u>3 (ADAF₂)</u> <u>1 (ADAF₁₆₊)</u>
7.15 7.16 7.17	<u>Intake Rate (L/kg-day)</u>	<u>0.289</u>	<u>0.289</u>	<u>(2)</u>	<u>(2)</u>	<u>0.137(_{<2})</u> <u>0.047(_{2 to <16})</u> <u>0.039(₁₆₊)</u>
7.18 7.19 7.20 7.21	<u>Endpoints</u>	<u>developmental (E), male reproductive system (E)</u>	<u>developmental (E), male reproductive system (E)</u>	<u>developmental (E), male reproductive system (E)</u>	<u>developmental (E), male reproductive system (E)</u>	<u>cancer</u>

7.22 Subp. 11e. Dimethenamid and Dimethenamid-p.7.23 CAS numbers: 87674-68-8 and 163515-14-87.24 Year Adopted: 20157.25 Volatility: Moderate

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>	
7.26 7.27	<u>HRL (µg/L)</u>	<u>ND</u>	<u>600</u>	<u>600 (2)</u>	<u>300</u>	<u>NA</u>
7.28 7.29	<u>RfD (mg/kg-day)</u>	<u>=</u>	<u>0.34</u>	<u>(2)</u>	<u>0.060</u>	<u>=</u>
7.30	<u>RSC</u>	<u>=</u>	<u>0.5</u>	<u>(2)</u>	<u>0.2</u>	<u>=</u>

8.1	SF (per mg/kg-day)	=	=	=	=	=
8.2						
8.3	ADAF or AF_{lifetime}	=	=	=	=	=
8.4						
8.5	Intake Rate (L/kg-day)	=	<u>0.289</u>	(2)	<u>0.043</u>	=
8.6						
8.7	Endpoints	=	developmental, female reproductive system, hepatic (liver) system, nervous system	developmental, female reproductive system, hepatic (liver) system, nervous system	hepatic (liver) system	=
8.8						
8.9						
8.10						
8.11						
8.12						

8.13 Subp. 12. [See repealer.]

8.14 [For text of subps 12a to 13, see M.R.]

8.15 Subp. 14. **Pentachlorophenol (PCP).**

8.16 CAS number: 87-86-5

8.17 Year Adopted: ~~2009~~ 2015

8.18 Volatility: ~~Nonvolatile~~ Low

8.19 MCL-based HRL: 1 µg/L

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>	
8.20						
8.21	HRL (µg/L)	<u>7</u>	<u>7</u>	<u>7</u> (2)	<u>7</u> (2)	<u>0.3</u>
8.22	RfD (mg/kg-day)	<u>0.0040</u>	<u>0.0040</u>	(2)	(2)	=
8.23						
8.24	RSC	<u>0.5</u>	<u>0.5</u>	(2)	(2)	=
8.25	SF (per mg/kg-day)	=	=	=	=	<u>0.4</u>
8.26						
8.27	ADAF or AF_{lifetime}	=	=	=	=	<u>10</u> (ADAF _{<2}) <u>3</u> (ADAF ₂) to <16 <u>1</u> (ADAF ₁₆₊)
8.28						
8.29						
8.30						
8.31						
8.32						

9.1	<u>Intake Rate</u> <u>(L/kg-day)</u>	<u>0.289</u>	<u>0.289</u>	<u>(2)</u>	<u>(2)</u>	<u>0.137</u> (<u>2</u>)
9.2						<u>0.047</u> (<u>2</u> to
9.3						<u><16</u>)
9.4						<u>0.039</u> (<u>16+</u>)
9.5	<u>Endpoints</u>	<u>developmental,</u>	<u>developmental</u>	<u>developmental</u>	<u>developmental</u>	<u>cancer</u>
9.6		<u>thyroid (E)</u>	<u>(E), thyroid (E)</u>	<u>(E), hepatic</u>	<u>(E), hepatic</u>	
9.7				<u>(liver) system,</u>	<u>(liver) system,</u>	
9.8				<u>immune</u>	<u>immune</u>	
9.9				<u>system, male</u>	<u>system, male</u>	
9.10				<u>reproductive</u>	<u>reproductive</u>	
9.11				<u>system, thyroid</u>	<u>system, thyroid</u>	
9.12			<u>(E)</u>	<u>(E)</u>		

[For text of subps 14a to 17, see M.R.]

Subp. 17a. **Sulfamethazine (includes sodium salt form).**

CAS number: 57-68-1 (1981-58-4)

Year Adopted: 2015

Volatility: Nonvolatile

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>	
9.18						
9.19	<u>HRL (µg/L)</u>	<u>ND</u>	<u>100</u>	<u>100 (2)</u>	<u>100 (2)</u>	<u>NA</u>
9.20	<u>RfD</u>	=	<u>0.040</u>	<u>(2)</u>	<u>(2)</u>	=
9.21	<u>(mg/kg-day)</u>					
9.22	<u>RSC</u>	=	<u>0.8</u>	<u>(2)</u>	<u>(2)</u>	=
9.23	<u>SF (per</u>	=	=	=	=	=
9.24	<u>mg/kg-day)</u>					
9.25	<u>ADAF or</u>	=	=	=	=	=
9.26	<u>AF</u> _{lifetime}					
9.27	<u>Intake Rate</u>	=	<u>0.289</u>	<u>(2)</u>	<u>(2)</u>	=
9.28	<u>(L/kg-day)</u>					
9.29	<u>Endpoints</u>	=	<u>thyroid</u>	<u>thyroid</u>	<u>thyroid</u>	=

[For text of subps 18 to 19, see M.R.]

Subp. 20. **1,1,2-Trichloroethylene (TCE).**

10.1 CAS number: 79-01-6
 10.2 Year Adopted: ~~2009~~ 2015
 10.3 Volatility: High
 10.4 MCL-based HRL: 5 µg/L

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>
<u>HRL (µg/L)</u>	<u>ND</u>	<u>0.4</u>	<u>0.4</u>	<u>0.4 (3)</u>	<u>2</u>
<u>RfD (mg/kg-day)</u>	<u>=</u>	<u>0.00052</u>	<u>0.00017</u>	<u>(3)</u>	<u>=</u>
<u>RSC</u>	<u>=</u>	<u>0.2</u>	<u>0.2</u>	<u>(3)</u>	<u>=</u>
<u>SF (per mg/kg-day)</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>0.05</u>
<u>ADAF or AF_{lifetime}</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>10 (ADAF_{<2})</u> <u>3 (ADAF₂)</u> <u>1 (ADAF₁₆₊)</u> <u>to <16</u>
<u>Intake Rate (L/kg-day)</u>	<u>=</u>	<u>0.289</u>	<u>0.077</u>	<u>(3)</u>	<u>0.137(2)</u> <u>0.047(2 to <16)</u> <u>0.039(16+)</u>
<u>Endpoints</u>	<u>=</u>	<u>developmental, immune system</u>	<u>developmental, immune system</u>	<u>developmental, immune system</u>	<u>cancer</u>

[For text of subps 21 to 24, see M.R.]

4717.7865 HEALTH RISK LIMITS FOR TRICLOSAN.

Subpart 1. Purpose. Notwithstanding the purpose and scope of health risk limits described in part 4717.7810, and as authorized by Laws 2013, chapter 137, article 2, section 8, the following values are adopted as health risk limits for triclosan.

Subp. 2. Triclosan.

CAS number: 3380-34-5
 Year Adopted: 2015
 Volatility: Nonvolatile

	<u>Acute</u>	<u>Short-term</u>	<u>Subchronic</u>	<u>Chronic</u>	<u>Cancer</u>	
11.1 11.2	<u>HRL (µg/L)</u>	<u>ND</u>	<u>50</u>	<u>50 (2)</u>	<u>50 (2)</u>	<u>NA</u>
11.3 11.4	<u>RfD (mg/kg-day)</u>	<u>=</u>	<u>0.067</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
11.5	<u>RSC</u>	<u>=</u>	<u>0.2</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
11.6 11.7	<u>SF (per mg/kg-day)</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
11.8 11.9	<u>ADAF or AF_{lifetime}</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>=</u>
11.10 11.11	<u>Intake Rate (L/kg-day)</u>	<u>=</u>	<u>0.289</u>	<u>(2)</u>	<u>(2)</u>	<u>=</u>
11.12 11.13 11.14 11.15 11.16 11.17 11.18	<u>Endpoints</u>	<u>=</u>	<u>developmental, female reproductive system (E), hepatic (liver) system, thyroid (E)</u>	<u>developmental, female reproductive system (E), hepatic (liver) system, thyroid (E)</u>	<u>developmental, female reproductive system (E), hepatic (liver) system, thyroid (E)</u>	<u>=</u>

11.19 **REPEALER.** Minnesota Rules, parts 4717.7500, subparts 19, 21, and 32; and 4717.7860,
 11.20 subpart 12, are repealed.